Drugs that contain Abemaciclib
1. Verzenio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 12, 2024 |
| New Indication(I-877) | Oct 12, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2022 |
| New Indication(I-768) | Feb 26, 2021 |
NCE-1 date: 28 September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the...
Dosage: TABLET;ORAL
More Information on Dosage
VERZENIO family patents
